Component

Osteoprotegerin / TNFRSF11B / OPG

Independent biological entity. Read linked claims for experimental scope and context.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Osteoprotegerin bound RANKL/ODF and blocked its osteoclastogenic activity in the mouse culture system.

    Osteoprotegerin / TNFRSF11B / OPG → RANK ligand / TNFSF11 source_derived_draftungraded
    Experimental context and source evidence
    compartment_description
    Extracellular space
    experimental_model
    Ligand identification and inhibition assays
    limitations
    The experiment establishes ligand sequestration in this system, not clinical fracture protection.
    nutrient_topic
    Calcium research collection; topical membership is not evidence of a direct dietary effect. · Calcium
    organism
    Mus musculus cell system
    plain_language
    OPG can intercept the signal that promotes bone-resorbing cells.
    primary_references
    [yasuda1998] Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL (1998). https://pmc.ncbi.nlm.nih.gov/articles/PMC19881/ DOI: 10.1073/pnas.95.7.3597
    tissue_or_cell_type
    Stromal and osteoclast-precursor cultures

    Calcium: mechanism-first literature curation (2026-09-17) · lines 1047–1057

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Ligand identification and inhibition assays · source_derived_draft · unverified_draft

    ### opg-binds-rankl Osteoprotegerin bound RANKL/ODF and blocked its osteoclastogenic activity in the mouse culture system. Condition category: normal nutrient_topic: Calcium research collection; topical membership is not evidence of a direct dietary effect. plain_language: OPG can intercept the signal that promotes bone-resorbing cells. organism: Mus musculus cell system tissue_or_cell_type: Stromal and osteoclast-precursor cultures experimental_model: Ligand identification and inhibition assays limitations: The experiment establishes ligand sequestration in this system, not clinical fracture protection. compartment_description: Extracellular space [yasuda1998] Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL (1998). https://pmc.ncbi.nlm.nih.gov/articles/PMC19881/ DOI: 10.1073/pnas.95.7.3597
    Complete structured claim and evidence

  2. Exogenous OPG blocked retinoic-acid-stimulated labelled calcium release from calvarial bone.

    Osteoprotegerin / TNFRSF11B / OPG → Osteoclastic bone resorption source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Vitamin A/RANKL -> calcium release.
    experimental_model
    Same organ culture.
    limitations
    Preparation-specific causal intervention.
    nutrient_topic
    Vitamin A research collection; topical membership is not evidence of a direct dietary effect. · Vitamin A
    organism
    Mus musculus
    plain_language
    Blocking the RANKL signal interrupted the measured resorption response.
    primary_references
    [va-conaway2011] Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor (2011). https://pubmed.ncbi.nlm.nih.gov/21715325/ DOI: 10.1074/jbc.m111.247734
    tissue_or_cell_type
    Bone

    Vitamin A: forms, mechanisms, deficiency and excess (2026-09-17) · lines 1626–1636

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Same organ culture. · source_derived_draft · unverified_draft

    ### va-opg-blocks-retinoid-calcium-release Exogenous OPG blocked retinoic-acid-stimulated labelled calcium release from calvarial bone. Condition category: normal nutrient_topic: Vitamin A research collection; topical membership is not evidence of a direct dietary effect. plain_language: Blocking the RANKL signal interrupted the measured resorption response. organism: Mus musculus tissue_or_cell_type: Bone experimental_model: Same organ culture. limitations: Preparation-specific causal intervention. cross_nutrient: Vitamin A/RANKL -> calcium release. [va-conaway2011] Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor (2011). https://pubmed.ncbi.nlm.nih.gov/21715325/ DOI: 10.1074/jbc.m111.247734
    Complete structured claim and evidence

What acts on it

  1. In long-term adult human primary osteoblast cultures, strontium ranelate increased the OPG/RANKL ratio and an OPG secretory response.

    Strontium ranelate → Osteoprotegerin / TNFRSF11B / OPG source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Human culture, OPG ELISA and gene-expression assays.
    limitations
    Ratio change is not itself a direct measurement of osteoclast resorption.
    nutrient_topic
    Strontium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Strontium
    plain_language
    Bone-forming cells can change the signals reaching bone-resorbing cells.
    primary_references
    Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. · 2009 · https://pubmed.ncbi.nlm.nih.gov/18763010/ · DOI 10.1007/s00198-008-0728-6

    Strontium: calcium interactions, cellular mechanisms and mineralization (2026-09-19) · lines 198–204

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human culture, OPG ELISA and gene-expression assays. · source_derived_draft · unverified_draft

    ## strontium-human-opg Bone-forming cells can change the signals reaching bone-resorbing cells. In long-term adult human primary osteoblast cultures, strontium ranelate increased the OPG/RANKL ratio and an OPG secretory response. Model: Human culture, OPG ELISA and gene-expression assays. Limitations: Ratio change is not itself a direct measurement of osteoclast resorption. Evidence access: Primary abstract Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. · 2009 · https://pubmed.ncbi.nlm.nih.gov/18763010/ · DOI 10.1007/s00198-008-0728-6
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Retinoic acid increased RANKL and the RANKL/OPG ratio in mouse calvarial cultures; receptor-selective results implicated RARalpha.

    All-trans-retinoic acid → RANK ligand / TNFSF11 source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Retinoid signaling -> calcium-store remodeling.
    experimental_model
    Neonatal mouse bone organ culture.
    limitations
    Receptor pharmacology is not proof of a human dietary effect.
    nutrient_topic
    Vitamin A research collection; topical membership is not evidence of a direct dietary effect. · Vitamin A
    organism
    Mus musculus
    plain_language
    A vitamin A metabolite increased a signal that promotes bone resorption.
    primary_references
    [va-conaway2011] Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor (2011). https://pubmed.ncbi.nlm.nih.gov/21715325/ DOI: 10.1074/jbc.m111.247734
    tissue_or_cell_type
    Calvarial bone

    Vitamin A: forms, mechanisms, deficiency and excess (2026-09-17) · lines 1614–1624

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Neonatal mouse bone organ culture. · source_derived_draft · unverified_draft

    ### va-rar-alpha-rankl-bone Retinoic acid increased RANKL and the RANKL/OPG ratio in mouse calvarial cultures; receptor-selective results implicated RARalpha. Condition category: normal nutrient_topic: Vitamin A research collection; topical membership is not evidence of a direct dietary effect. plain_language: A vitamin A metabolite increased a signal that promotes bone resorption. organism: Mus musculus tissue_or_cell_type: Calvarial bone experimental_model: Neonatal mouse bone organ culture. limitations: Receptor pharmacology is not proof of a human dietary effect. cross_nutrient: Retinoid signaling -> calcium-store remodeling. [va-conaway2011] Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor (2011). https://pubmed.ncbi.nlm.nih.gov/21715325/ DOI: 10.1074/jbc.m111.247734
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards